Patents Examined by Sharon Wen
-
Patent number: 9879093Abstract: Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.Type: GrantFiled: December 20, 2012Date of Patent: January 30, 2018Assignees: ADAERATA, LIMITED PARTNERSHP, NATIONAL RESEARCH COUNCIL OF CANADAInventors: Nabil G. Seidah, Jianbing Zhang
-
Patent number: 9850319Abstract: Isolated monoclonal antibodies and or antigen binding fragments thereof are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at N3 (3-pHis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed. Methods are also disclosed for using these antibodies, such as for detection of polypeptides comprising a histidine phosphorylated at N3 (3-pHis). In some embodiments, the methods can be used to investigate signal transduction pathways.Type: GrantFiled: July 1, 2015Date of Patent: December 26, 2017Assignees: Salk Institute for Biological Studies, SanofiInventors: Tony Hunter, Stephen Rush Fuhs, Jill Meisenhelder, Jacques Mauger, Magda Stankova, Fahad Al-Obeidi, Robert A. Binne
-
Patent number: 9809646Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: GrantFiled: April 14, 2017Date of Patent: November 7, 2017Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9803026Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.Type: GrantFiled: April 27, 2012Date of Patent: October 31, 2017Assignee: SBI Biotech Co., Ltd.Inventors: Tomohide Yamazaki, Jing Zhao, Koji Ishida, Yasue Shibata, Minkwon Cho, Mayuki Endo
-
Patent number: 9789173Abstract: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.Type: GrantFiled: June 4, 2014Date of Patent: October 17, 2017Assignee: IRX Therapeutics, Inc.Inventor: John W. Hadden
-
Patent number: 9789172Abstract: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.Type: GrantFiled: June 4, 2014Date of Patent: October 17, 2017Assignee: IRX Therapeutics, Inc.Inventor: John W. Hadden
-
Patent number: 9765141Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: GrantFiled: March 21, 2014Date of Patent: September 19, 2017Assignee: E. R. SQUIBB & SONS, L.L.C.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
-
Patent number: 9746474Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.Type: GrantFiled: May 2, 2014Date of Patent: August 29, 2017Assignee: DINONA INC.Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
-
Patent number: 9738727Abstract: The invention provides anti-HtrA1 antibodies and methods of using the same.Type: GrantFiled: October 12, 2012Date of Patent: August 22, 2017Assignee: Genentech, Inc.Inventors: Yan Wu, Menno van Lookeren-Campagne, Daniel Kirchhofer, Michael Terry Lipari, Kenneth J. Katschke, Jr., Paul M. Moran, Scott Stawicki, Wei-Ching Liang
-
Patent number: 9731035Abstract: The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formula Ab-X wherein the group Ab comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the disease state, the group X comprises an imaging agent.Type: GrantFiled: March 11, 2013Date of Patent: August 15, 2017Assignee: Purdue Research FoundationInventors: Philip S. Low, Andrew R. Hilgenbrink
-
Patent number: 9732156Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).Type: GrantFiled: February 28, 2013Date of Patent: August 15, 2017Assignee: Gilead Biologics, Inc.Inventors: Joanne I. Adamkewicz, Victoria Smith, Zung Thai, Michael J. Hawkins
-
Patent number: 9732158Abstract: The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.Type: GrantFiled: February 25, 2014Date of Patent: August 15, 2017Assignee: NMDX, LLCInventor: Patrick J. Muraca
-
Patent number: 9675625Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: June 17, 2013Date of Patent: June 13, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sakai, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Patent number: 9676867Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.Type: GrantFiled: May 8, 2013Date of Patent: June 13, 2017Assignee: Dana-Farber Cancer Institute Inc.Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu
-
Patent number: 9675679Abstract: The invention features immunoconjugates for impeding weight gain and treating obesity in a subject. The immuno-conjugates comprise particular ghrelin polypeptides and a suitable carrier moiety.Type: GrantFiled: August 1, 2007Date of Patent: June 13, 2017Assignee: The Scripps Research InstituteInventors: Eric P. Zorrilla, Michael M. Meijler, Kim D. Janda
-
Patent number: 9657093Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: GrantFiled: January 25, 2016Date of Patent: May 23, 2017Assignee: Immunomedics, Inc.Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9657109Abstract: Described herein are peptides from secretory phospholipase A2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.Type: GrantFiled: November 2, 2012Date of Patent: May 23, 2017Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jordan Marshall Sand, Mark Eric Cook, Daniel Elmer Butz
-
Patent number: 9631020Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.Type: GrantFiled: June 4, 2012Date of Patent: April 25, 2017Assignees: Korea Research Institute of Bioscience and Biotechnology, Y-Biologics Inc.Inventors: Young Woo Park, Ki Won Jo, Chan Woong Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Seon Ha Yun, Kyu Won Cho, Mi Ra Park
-
Patent number: 9617323Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.Type: GrantFiled: June 7, 2010Date of Patent: April 11, 2017Inventor: Joshua Rabbani
-
Patent number: 9605079Abstract: The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.Type: GrantFiled: April 18, 2011Date of Patent: March 28, 2017Assignee: MEDVET SCIENCE PTY LTD.Inventors: Simon Barry, Doreen Krumbiegel, Nicola Ga-Ling Eastaff-Leung, Ian Cameron Nicholson, Heddy Zola